Physician profile
Marvin E Urbina
NPI 1225129281
$6,369.09
in general payments reported to CMS, 2019-2025
27 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,620 · 2020: $318 · 2021: $1,231 · 2022: $1,008 · 2023: $540 · 2024: $603 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,502.69 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,226.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $488.63 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $344.57 | 2020-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $335.73 | 2020-2022 | |
| Madrigal Pharmaceuticals | $299.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Xeris Pharmaceuticals, INC. | $283.94 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Sanofi-Aventis U.S. LLC | $278.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $276.28 | 2019-2023 | |
| Glaxosmithkline, LLC. | $263.41 | 2019-2021 | |
| Lilly USA, LLC | $150.82 | 2022-2025 | Jardiance, Mounjaro, Kisunla |
| Amarin Pharma, INC. | $125.53 | 2021 | |
| Shield Therapeutics INC | $96.79 | 2023-2025 | Accrufer |
| Sunovion Pharmaceuticals INC. | $92.04 | 2021-2022 | |
| Exact Sciences Corporation | $78.03 | 2023-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $73.44 | 2019-2024 | Veozah |
| Abbott Laboratories | $71.38 | 2023-2024 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Genzyme Corporation | $63.62 | 2024 | |
| Abbvie INC. | $58.88 | 2021-2023 | Ubrelvy |
| Dexcom, INC. | $46.72 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.31 | 2021 | |
| Sumitomo Pharma America, INC. | $34.63 | 2023-2025 | Gemtesa |
| Pfizer INC. | $27.65 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.06 | 2021 | |
| Optos, INC. | $26.80 | 2021 | |
| Optinose US, INC. | $26.78 | 2025 | |
| Allergan, INC. | $26.26 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Urbina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.